Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | MITF | O75030 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766911 | 0.95 | LMNA (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL8767682 | 0.93 | LMNA (0.59) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL10828017 | 0.92 | LMNA (0.58) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL8766893 | 0.92 | LMNA (0.58) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL8645421 | 0.92 | LMNA (0.58) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL22773415 | 0.88 | LMNA (0.46) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL11500794 | 0.88 | LMNA (0.62) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL19659872 | 0.87 | LMNA (0.45) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL13531143 | 0.86 | LMNA (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF | |
| SCHEMBL7991466 | 0.86 | LMNA (0.61) | LMNAHSD17B10SMN1; SMN2MAPTMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2024-07-25 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| CN-113024466-A | Tetra-substituted olefin compound and use thereof | 卫材 R&D 管理有限公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2008070463-A2 | ENDOXIFEN METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2007098090-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH N-OXIDES OF ESTROGEN RECEPTOR MODULATORS | NOVACEA, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2004012723-A1 | TAMOXIFEN CONTAINING NOT MORE THAN 0.006% E-ISOMER | KYMED GB LTD. (GB) | 2004-02-12 | — | — | WO | disclosed |
| US-6172263-B1 | PURIFICATION; SOLVENT EXTRACTION WITH METHANOL; CRYSTALLIZATION | BRADFORD UNIVERSITY (GB) | 2001-01-09 | — | — | US | disclosed |
| EP-0998447-A1 | TAMOXIFEN AND ANALOGUES THEREOF | UNIVERSITY OF BRADFORD (GB) | 2000-05-10 | — | — | EP | disclosed |
| US-5962743-A | Process for preparing acylaromatic compounds | CATALYTICA PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999005088-A1 | TAMOXIFEN AND ANALOGUES THEREOF | UNIVERSITY OF BRADFORD (GB) | 1999-02-04 | — | — | WO | disclosed |
| EP-0260066-B1 | TAMOXIFEN DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-05-09 | — | — | EP | disclosed |
| US-4839155-A | Iodotamoxifen derivatives and use for estrogen receptor-positive breast cancer detection and therapy | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-06-13 | — | — | US | disclosed |
| EP-0260066-A1 | Tamoxifen derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | GAA, GBA1, GBA2 | LMNA 95/4885HSD17B10 2878/4885SMN1; SMN2 114/4885 |
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | GAA, GBA1, GBA2 | LMNA 95/4885HSD17B10 2878/4885SMN1; SMN2 114/4885 |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | EEF2K, LITAF, RAPGEF3 | LMNA 948/4885HSD17B10 3559/4885SMN1; SMN2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.